Patient’s recognition level of medical terms as estimated by pharmacists

Yoshida, Yasuko; Yoshida, Yoshitoku

doi:10.1007/s12199-014-0408-4

Environmental Health and Preventive Medicine

Table 2 Difference between medical doctors and pharmacists with respect to patients’ recognition level of the 90 medical terms

From: Patient’s recognition level of medical terms as estimated by pharmacists

Group	Medical term	Estimated by the medical doctors (n = 211)	Estimated by the pharmacists (n = 212)
Group	Medical term	Know^a (%)	Know^a (%)	test
A	Critical condition	65.9	77.8	**
	Prognosis	54.5	71.7	**
	Tolerance	49.3	65.1	**
	Aspiration	45.5	53.8	n.s.
	MRSA	44.1	50.5	n.s.
	Biopsy	37.9	42.5	n.s.
	Infiltration	33.2	39.6	n.s.
	Evidence	30.3	39.6	n.s.
	Remission	30.3	39.2	n.s.
	Deliria	30.3	37.7	n.s.
	Ileus	29.4	32.5	n.s.
	ADL	28.9	29.7	n.s.
	COPD	24.6	40.6	**
B1	Virus	78.2	89.2	**
	Metabolic syndrome	74.9	83.0	*
	Tumor	71.1	77.4	n.s.
	Insulin	70.6	82.5	**
	Ulcer	68.7	73.6	n.s.
	Inflammation	66.4	89.2	**
	Be taken as needed	62.1	70.3	n.s.
	Renal insufficiency	59.2	68.4	n.s.
	Geriatric health services facilities	55.0	59.9	n.s.
	Steroid	52.1	70.8	**
	Tumor marker	46.9	54.7	n.s.
	Group home	44.1	50.5	n.s.
	Symptomatic treatment	42.7	56.6	**
	Sepsis	35.5	38.2	n.s.
	Connective tissue disease	33.2	42.0	n.s.
B2	Diabetes	85.3	92.9	*
	Adverse drug effect	82.5	89.2	n.s.
	Malignant tumor	81.5	87.7	n.s.
	Asthma	80.6	87.3	n.s.
	Arteriosclerosis	80.1	86.3	n.s.
	Depression	75.8	84.9	*
	Heat stroke	72.0	87.3	**
	Polyp	60.7	71.7	*
	Brain death	59.7	78.3	**
	Cirrhosis	58.8	70.3	*
	Death with dignity	51.2	58.5	n.s.
	Chemotherapy	48.3	53.3	n.s.
	Jaundice	47.9	59.9	*
	Anamnesis	42.7	50.5	n.s.
	Antibody	40.8	49.1	n.s.
	Clinical trial	34.6	49.1	**
	Congestion	32.2	45.8	**
B3	Anemia	72.5	91.0	**
	Complication	65.4	69.3	n.s.
	Shock	43.6	59.0	**
C	MRI	51.7	50.9	n.s.
	Informed consent	44.5	46.7	n.s.
	Second opinion	44.1	54.2	*
	Palliative care	35.1	40.1	n.s.
	Guidelines	34.6	39.2	n.s.
	PET	32.7	34.0	n.s.
	QOL	28.9	36.3	n.s.
	Primary care	25.1	26.9	n.s.
	Clinical pass	20.4	21.7	n.s.
D	Clinical investigation	29.9	39.2	n.s.
	Placebo	25.6	36.8	*
	Double blind trial	22.7	33.0	*
	Phase three clinical trial	15.2	20.3	n.s.
	Phase one clinical trial	14.7	23.1	*
	Phase two clinical trial	13.3	20.3	n.s.
	GCP	8.5	18.4	**
E	Anuresis/difficulty of urination	38.9	51.9	**
	Bleeding tendency	37.9	53.8	**
	Hypothyroidism	33.6	41.0	n.s.
	Thrombosis	32.2	40.1	n.s.
	Medicamentosus stomatitis	28.4	41.0	**
	Anaphylaxis	26.1	38.7	**
	Peripheral neuropathy	24.2	32.5	n.s.
	Nephrotic syndrome	24.2	31.6	n.s.
	Aplastic anemia	21.8	34.9	**
	Ataxia	20.9	28.8	n.s.
	Edema of lung	20.4	24.5	n.s.
	Interstitial pneumonia	19.9	31.1	*
	Rhabdomyolysis	19.9	31.1	*
	Ventricular tachycardia	19.9	19.8	n.s.
	Stevens-Johnson syndrome	19.4	29.7	*
	Agranulocytosis	19.4	26.4	n.s.
	Guillain–Barre syndrome	19.4	21.7	n.s.
	Angioedema	19.0	25.5	n.s.
	Drug-related parkinsonism	18.5	26.9	*
	Malignant syndrome	17.5	28.3	*
	Alveolar hemorrhage	17.1	17.0	n.s.
	Pseudohyperaldosteronism	16.1	25.5	*
	Dyskinesia	16.1	20.3	n.s.
	Toxic necrolysis	15.6	23.1	n.s.
	Akathisia	12.3	17.0	n.s.
	Hand-and-feet syndrome	11.8	21.2	*

^a1 means “I do not think that patients know”. 3 means “I cannot tell clearly whether the patient knows or not”, 5 means “I think that patients know.” In analyzing, 4 and 5 out of 1–5 were used as “I think that patients know”
n.s. not significant
χ ² test: ** p < 0.01,* p < 0.05

Back to article page

ISSN: 1347-4715

Contact us

General enquiries: info@biomedcentral.com